- Trials with a EudraCT protocol (74)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
74 result(s) found for: CD4 CD8 ratio.
Displaying page 1 of 4.
EudraCT Number: 2019-000199-41 | Sponsor Protocol Number: GESIDA10918 | Start Date*: 2019-07-10 | |||||||||||
Sponsor Name:Fundación SEIMC-GESIDA | |||||||||||||
Full Title: A phase IV, multicenter, open and randomized study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in patients with type 1 HIV i... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021785-30 | Sponsor Protocol Number: A4001095 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Prematurely Ended) NL (Completed) PT (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000061-14 | Sponsor Protocol Number: BCN04-DASA | Start Date*: 2023-05-26 | |||||||||||
Sponsor Name:Institut de Recerca Germans Trias i Pujol | |||||||||||||
Full Title: Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People with HIV under Antiretroviral Treatment | |||||||||||||
Medical condition: Human immunodeficiency virus (HIV) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007057-42 | Sponsor Protocol Number: A4M108119 | Start Date*: 2007-05-29 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast | ||||||||||||||||||
Medical condition: relapsing forms of multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002722-36 | Sponsor Protocol Number: RAGTIME | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:FUNDACIÓ LLUITA CONTRA LA SIDA | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of Raltegravir intensification (1.200 mg QD) on the gut microbiota of chronically HIV-1 infected subject over time... | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003686-18 | Sponsor Protocol Number: GESIDA11720 | Start Date*: 2021-04-29 |
Sponsor Name:Seimc-Gesida Foundation | ||
Full Title: DTG/3TC vs. BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-005226-11 | Sponsor Protocol Number: FIS-TAR-01-2016 | Start Date*: 2017-04-04 | ||||||||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI) | ||||||||||||||||||
Full Title: Phase 4 clinical trial, randomized to evaluate the effect on immune recovery of triple antiretroviral maintenance therapy (elvitegravir / cobicistat 150/150 mg + tenofovir + emtricitabine alapenami... | ||||||||||||||||||
Medical condition: Adult patients with HIV infection on stable therapy (≥ 6 months) with triple therapy and undetectable viremia for ≥ 1 year. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002876-26 | Sponsor Protocol Number: 2017-002876-26 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:South Tees Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC) | |||||||||||||
Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005093-11 | Sponsor Protocol Number: IVVAC-3S/P2 | Start Date*: 2015-01-14 | |||||||||||
Sponsor Name:InnaVirVax | |||||||||||||
Full Title: Multicentre, open-label, phase I/IIa clinical study of an immunoprotective therapeutic vaccine candidate (VAC-3S) in Human Immunodeficiency Virus type 1 (HIV-1) chronically infected patients virol... | |||||||||||||
Medical condition: Chronically infected HIV-1 patients under viral control on Anti-Retroviral therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004578-40 | Sponsor Protocol Number: SSAT066 | Start Date*: 2015-01-26 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal ... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000358-26 | Sponsor Protocol Number: BETAF-RED | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer | |||||||||||||
Full Title: Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults. | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000800-14 | Sponsor Protocol Number: FIS-TAR-01-2019 | Start Date*: 2020-02-07 | ||||||||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI) | ||||||||||||||||||
Full Title: Effectiveness of a dual therapy based on dolutegravir plus lamivudine on reduction of the viral reservoir, immune recovery and immune activation compared with a triple antiretroviral therapy based ... | ||||||||||||||||||
Medical condition: Adult patients with HIV infection without previous treatment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002104-18 | Sponsor Protocol Number: GID25 | Start Date*: 2007-08-27 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an I... | ||
Medical condition: Vaccination of adult subjects aged 18 to 40 years and elderly subjects aged 60 to 85 years with an inactivated, split-virion influenza vaccine administered via the intradermal route using Vaxigrip®... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004241-32 | Sponsor Protocol Number: EDOLAS | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | |||||||||||||
Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression | |||||||||||||
Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003299-15 | Sponsor Protocol Number: METFORAGING | Start Date*: 2021-10-19 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital La Paz | ||
Full Title: A double blinded, phase II, placebo controlled, single center randomized clinical trial to evaluate metformin compared with placebo for reversal of accelerated biological aging in persons living wi... | ||
Medical condition: Patients with HIV and accelerated biological aging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004665-42 | Sponsor Protocol Number: ST 200 DS 05-002 | Start Date*: 2006-03-17 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: Evaluation of the efficacy and tollerability of long-term somministration of Acetyl-l-carnitine in the treatment of HIV related lipodystrophy.Parallel group, randomized, double blind, controlled ve... | |||||||||||||
Medical condition: HIV related LIPODYSTROPHY. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001515-22 | Sponsor Protocol Number: S54226 | Start Date*: 2012-05-16 |
Sponsor Name:Katholieke Universiteit Leuven | ||
Full Title: Cytomegalovirus infection and the influenza vaccination response in older persons | ||
Medical condition: Humoral and cellular immune response after vaccination in older people | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004195-19 | Sponsor Protocol Number: CREPATS10 | Start Date*: 2020-07-07 | |||||||||||
Sponsor Name:Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS) | |||||||||||||
Full Title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma vire... | |||||||||||||
Medical condition: HIV disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003208-11 | Sponsor Protocol Number: CRF002 | Start Date*: 2020-03-04 | |||||||||||
Sponsor Name:Chelsea and Westminster Hospital NHS Foundation Trust | |||||||||||||
Full Title: Efficacy of BIC/F/TAF versus standard of care in the treatment of new HIV infection diagnoses in the context of 'test and treat' | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023192-26 | Sponsor Protocol Number: MVC-001-MiTox | Start Date*: 2011-04-20 | ||||||||||||||||
Sponsor Name:mib Dienstleistungsgesellschaft mbH | ||||||||||||||||||
Full Title: EFFECT OF SWITCHING FROM NRTIS TO MARAVIROC ON NRTI-ASSOCIATED MITCHONDRIAL TOXICITY AND IMMUNE ACTIVATION | ||||||||||||||||||
Medical condition: Increases in inflammatory biomarkers have been associated with various non-AIDS complications such as cardiovascular events. Maraviroc has no known toxic effects on mitochondria and has been shown ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
